Mylan to supply substances for production of anti-HIV drugs in Russia

The Indian unit of beleaguered Netherlands-incorporated drugmaker Mylan (Nasdaq: MYL) has reached an agreement with Natsimbio, Russia’s leading producer of vaccines, on the supplies of its active substances for the production of anti-HIV drugs in Russia, according to the companies, reports The Pharma Letter's local correspondent.

Sergei Chemezov, chief executive of Russian state corporation Rostec, which is a parental company of Natsimbio, said the agreement also involves the transfer of technology for the production of vaccines to Natsimbio. That will help to establish the production of anti-HIV drugs at the facilities of the Russian company.

The launch of production will help to reduce the cost of drugs for HIV treatment in the Russian market, Mr Chemezov said.